ABSTRACT
Background: An early etiological diagnosis of hearing loss positively impacts children's quality of life including language and cognitive development. Even though hearing loss associates with extremely high genetic and allelic heterogeneity, several studies have proven that Next-Generation Sequencing (NGS)-based gene panel testing significantly reduces the time between onset and diagnosis. Methods: In order to assess the clinical utility of our custom NGS GHELP panel, the prevalence of pathogenic single nucleotide variants, indels or copy number variants was assessed by sequencing 171 nuclear and 8 mitochondrial genes in 155 Spanish individuals with hearing loss. Results: A genetic diagnosis of hearing loss was achieved in 34% (52/155) of the individuals (5 out of 52 were syndromic). Among the diagnosed cases, 87% (45/52) and 12% (6/52) associated with autosomal recessive and dominant inheritance patterns respectively; remarkably, 2% (1/52) associated with mitochondrial inheritance pattern. Although the most frequently mutated genes in this cohort were consistent with those described in the literature (GJB2, OTOF or MYO7A), causative variants in less frequent genes such as TMC1, FGF3 or mitCOX1 were also identified. Moreover, 5% of the diagnosed cases (3/52) were associated with pathogenic copy number variants. Conclusion: The clinical utility of NGS panels that allows identification of different types of pathogenic variants-not only single nucleotide variants/indels in both nuclear and mitochondrial genes but also copy number variants-has been demonstrated to reduce the clinical diagnostic odyssey in hearing loss. Thus, clinical implementation of genomic strategies within the regular clinical practice, and, more significantly, within the newborn screening protocols, is warranted.
ABSTRACT
BACKGROUND: Patients with Multiple Sclerosis (MS) undergoing treatment with natalizumab (NTZ) are at risk of developing progressive multifocal leukoencephalopathy (PML) due to the reactivation of John Cunningham (JC) virus. A relevant characteristic among PML cases is the development of single nucleotide mutations in the VP1 gene of the causal JC virus. The identification of such mutations in timely manner can provide valuable information for MS management. OBJECTIVE: To identify mutations along the JC virus VP1 gene in MS patients undergoing treatment with NTZ, and correlate them with anti-JC virus antibody index. METHODS: Eighty-eight MS patients, one hundred twenty controls, and six patients with diagnosis of Human Immunodeficiency Virus (HIV) with and without secondary PML were included. JC virus was identified in peripheral blood mononuclear cells and cerebrospinal fluid by PCR. Amplification and sequencing of the entire length of the VP1 gene were performed in all positive clinical samples. RESULTS: In MS cases no mutations were observed in the JC virus VP1 gene, but it was positive in HIV controls with PML. Interestingly, the JC virus VP1 gene sequence derived from the HIV patients exhibited a non-silent substitution in position 186 (G â C), leading to an amino acid change (Lys â Asp). We did not find correlation between anti-JC virus antibody index and DNA viral detection. CONCLUSIONS: . The identification of single nucleotide mutants in the JC virus VP1 gene might be an early predictive marker to PML for efficient patient treatment and follow-up.
Subject(s)
JC Virus , Leukoencephalopathy, Progressive Multifocal , Multiple Sclerosis , HIV Infections , Humans , JC Virus/genetics , Leukocytes, Mononuclear , Multiple Sclerosis/complications , Multiple Sclerosis/drug therapy , Multiple Sclerosis/genetics , Mutation , Natalizumab/therapeutic useABSTRACT
Genome studies of diffuse large B-cell lymphoma (DLBCL) have revealed a large number of somatic mutations and structural alterations. However, the clinical significance of these alterations is still not well defined. In this study, we have integrated the analysis of targeted next-generation sequencing of 106 genes and genomic copy number alterations (CNA) in 150 DLBCL. The clinically significant findings were validated in an independent cohort of 111 patients. Germinal center B-cell and activated B-cell DLBCL had a differential profile of mutations, altered pathogenic pathways and CNA. Mutations in genes of the NOTCH pathway and tumor suppressor genes (TP53/CDKN2A), but not individual genes, conferred an unfavorable prognosis, confirmed in the independent validation cohort. A gene expression profiling analysis showed that tumors with NOTCH pathway mutations had a significant modulation of downstream target genes, emphasizing the relevance of this pathway in DLBCL. An in silico drug discovery analysis recognized 69 (46%) cases carrying at least one genomic alteration considered a potential target of drug response according to early clinical trials or preclinical assays in DLBCL or other lymphomas. In conclusion, this study identifies relevant pathways and mutated genes in DLBCL and recognizes potential targets for new intervention strategies.
Subject(s)
Genetic Variation , Genomics , Lymphoma, Large B-Cell, Diffuse/genetics , Lymphoma, Large B-Cell, Diffuse/metabolism , Signal Transduction , Adult , Aged , Antineoplastic Agents/pharmacology , Cell Line, Tumor , DNA Copy Number Variations , Female , Genomics/methods , High-Throughput Nucleotide Sequencing , Humans , Janus Kinases/metabolism , Lymphoma, Large B-Cell, Diffuse/drug therapy , Lymphoma, Large B-Cell, Diffuse/pathology , Male , Middle Aged , Mutation , Neoplasm Staging , Receptors, Notch/metabolism , STAT Transcription Factors/metabolism , Signal Transduction/drug effectsABSTRACT
Transformation of Waldenström's macroglobulinemia (WM) to diffuse large B-cell lymphoma (DLBCL) occurs in up to 10% of patients and is associated with an adverse outcome. Here we performed the first whole-exome sequencing study of WM patients who evolved to DLBCL and report the genetic alterations that may drive this process. Our results demonstrate that transformation depends on the frequency and specificity of acquired variants, rather than on the duration of its evolution. We did not find a common pattern of mutations at diagnosis or transformation; however, there were certain abnormalities that were present in a high proportion of clonal tumor cells and conserved during this transition, suggesting that they have a key role as early drivers. In addition, recurrent mutations gained in some genes at transformation (for example, PIM1, FRYL and HNF1B) represent cooperating events in the selection of the clones responsible for disease progression. Detailed comparison reveals the gene abnormalities at diagnosis and transformation to be consistent with a branching model of evolution. Finally, the frequent mutation observed in the CD79B gene in this specific subset of patients implies that it is a potential biomarker predicting transformation in WM.
Subject(s)
Biomarkers, Tumor/genetics , CD79 Antigens/genetics , Cell Transformation, Neoplastic/genetics , Exome , Lymphoma, Large B-Cell, Diffuse/genetics , Mutation , Neoplasm Proteins/genetics , Waldenstrom Macroglobulinemia/genetics , Aged , Aged, 80 and over , Female , Humans , Male , Middle AgedABSTRACT
OBJECTIVE: To evaluate the effect of all-trans retinoic acid (ATRA) as treatment for chemotherapy-induced peripheral neuropathy in an experimental animal model and in a randomized, double-blinded, controlled trial in patients with non-small-cell lung cancer (NSCLC). METHODS: Forty male Wistar rats were randomized in 5 groups: group A, control; groups B and C, treated with cisplatin; and groups D and E, treated with paclitaxel. ATRA (20 mg/kg PO) was administered for 15 days in groups C and E. We evaluated neuropathy and nerve regeneration-related morphologic changes in sciatic nerve, the concentration of nerve growth factor (NGF), and retinoic acid receptor (RAR)-α and RAR-ß expression. In addition, 95 patients with NSCLC under chemotherapy treatment were randomized to either ATRA (20 mg/m(2)/d) or placebo. Serum NGF, neurophysiologic tests, and clinical neurotoxicity were assessed. RESULTS: The experimental animals developed neuropathy and axonal degeneration, associated with decreased NGF levels in peripheral nerves. Treatment with ATRA reversed sensorial changes and nerve morphology; this was associated with increased NGF levels and RAR-ß expression. Patients treated with chemotherapy had clinical neuropathy and axonal loss assessed by neurophysiology, which was related to decreased NGF levels. ATRA reduced axonal degeneration demonstrated by nerve conduction velocity and clinical manifestations of neuropathy grades ≥2. CONCLUSIONS: ATRA reduced chemotherapy-induced experimental neuropathy, increased NGF levels, and induced RAR-ß expression in nerve. In patients, reduction of NGF in serum was associated with the severity of neuropathy; ATRA treatment reduced the electrophysiologic alterations. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that ATRA improves nerve conduction in patients with chemotherapy-induced peripheral neuropathy.
Subject(s)
Antineoplastic Agents/adverse effects , Carcinoma, Non-Small-Cell Lung/drug therapy , Disease Models, Animal , Lung Neoplasms/drug therapy , Polyneuropathies/chemically induced , Polyneuropathies/prevention & control , Tretinoin/therapeutic use , Animals , Carcinoma, Non-Small-Cell Lung/pathology , Carcinoma, Non-Small-Cell Lung/physiopathology , Double-Blind Method , Female , Humans , Hyperalgesia/chemically induced , Hyperalgesia/prevention & control , Lung Neoplasms/pathology , Lung Neoplasms/physiopathology , Male , Middle Aged , Polyneuropathies/physiopathology , Rats , Rats, WistarABSTRACT
We derive an exact Markovian kinetic equation for an oscillator linearly coupled to a heat bath, describing quantum Brownian motion. Our work is based on the subdynamics formulation developed by Prigogine and collaborators. The space of distribution functions is decomposed into independent subspaces that remain invariant under Liouville dynamics. For integrable systems in Poincaré's sense the invariant subspaces follow the dynamics of uncoupled, renormalized particles. In contrast, for nonintegrable systems, the invariant subspaces follow a dynamics with broken time symmetry, involving generalized functions. This result indicates that irreversibility and stochasticity are exact properties of dynamics in generalized function spaces. We comment on the relation between our Markovian kinetic equation and the Hu-Paz-Zhang equation.
ABSTRACT
An infectious bursal disease (IBD) outbreak occurred in the east region of Spain in the spring of 2002 and rapidly spread thorough the whole country, although proper vaccination programs were applied. In this report, 33 infectious bursal disease viruses (IBDVs) isolated from this outbreak were characterized by nucleotide sequencing of the VP2 gene hypervariable region and were compared with reference IBD strains and the 1990s Spanish IBDVs in order to determine possible emergence of IBDV isolates with modified antigenic or virulent properties. Moreover, histopathologic and immunohistochemical studies of those cases where bursal tissues were available were carried out. Of the 33 isolates, 23 were identified as very virulent IBDVs (vvIBDVs), whereas the other 10 isolates were classified as attenuated or intermediate virulence classical strains and could possibly be IBDV live vaccine strains used in the immunization of these chickens. Results of this study indicate that wIBDV isolates from the 2002 Spanish outbreak are closely related with those from the 1990s outbreak. However, acute IBD cases have not been reported in Spain during these 10 yr. Genetic, management, and environmental factors likely related with IBD reemergence in Spain are discussed. Moreover, our results indicate that good correlation exists between the IBDV subtype present in the field and the degree of lesions in bursa tissue, as well as the immunohistochemistry staining.
Subject(s)
Birnaviridae Infections/veterinary , Birnaviridae Infections/virology , Disease Outbreaks/veterinary , Infectious bursal disease virus/genetics , Poultry Diseases/epidemiology , Poultry Diseases/virology , Amino Acid Sequence , Animals , Birnaviridae Infections/epidemiology , Birnaviridae Infections/pathology , Chickens , Disease Outbreaks/statistics & numerical data , Genotype , Immunohistochemistry , Infectious bursal disease virus/isolation & purification , Molecular Sequence Data , Phylogeny , Poultry Diseases/pathology , Reverse Transcriptase Polymerase Chain Reaction , Sequence Analysis, DNA , Spain/epidemiology , Viral Structural Proteins/geneticsABSTRACT
BACKGROUND: Decreased production of nerve growth factor (NGF) may contribute to diabetic neuropathy; however, exogenous administration of NGF induces only a modest benefit. Retinoic acid (RA) promotes the endogenous expression of nerve growth factor and its receptor. We studied the effects of RA on diabetic neuropathy in mice with streptozotocin-induced diabetes. MATERIAL AND METHODS: One hundred and twenty National Institutes of Health (NIH) albino mice randomly separated into three groups (A, n = 30; B, n = 30; C, n = 60). Diabetes mellitus was induced with streptozotocin in groups A and B. Animals from group A received a subcutaneous injection of 25 microl of mineral oil daily for 90 days, while those from group B received a subcutaneous injection of 20 mg kg(-1) of all trans RA. Animals from group C were taken as controls. At the end of the experiment, blood glucose and NGF levels (both in serum and sciatic nerve) were measured. Two behavioural tests were conducted in a blind fashion to detect abnormalities of thermal and nociceptive thresholds. RESULTS: Contents of NGF in healthy untreated mice were 1490 +/- 190 pg mg(-1) in nerve and 113 +/- 67 pg mg(-1) in serum; in diabetic untreated mice the values were 697 +/- 219 pg mL(-1) in nerve and 55 +/- 41 pg mL(-1) in serum; and in diabetic mice treated with RA the values were 2432 +/- 80 pg mL(-1) in nerve and 235 +/- 133 pg mg(-1) in serum (P < 0.002). Ultrastructural evidence of nerve regeneration and sensitivity tests improved in diabetic mice treated with RA as compared with nontreated diabetic mice. CONCLUSION: Our findings indicate that administration of RA increases serum and nerve contents of NGF in diabetic mice and suggest a potential therapeutic role for retinoic acid in diabetic patients.
Subject(s)
Diabetes Mellitus, Experimental/metabolism , Diabetic Neuropathies/prevention & control , Nerve Growth Factor/metabolism , Tretinoin/therapeutic use , Animals , Blood Glucose/drug effects , Blood Glucose/metabolism , Diabetes Mellitus, Experimental/blood , Diabetes Mellitus, Experimental/pathology , Diabetic Neuropathies/metabolism , Diabetic Neuropathies/pathology , Male , Mice , Nerve Growth Factor/blood , Nerve Growth Factor/drug effects , Nerve Regeneration/drug effects , Sciatic Nerve/drug effects , Sciatic Nerve/metabolism , Sciatic Nerve/ultrastructureABSTRACT
Antecedentes: el tratamiento laparoscópico del cáncer colorrectal plantea controversias desde el punto de vista de la cirugía oncológica. El rol de esta vía de abordaje en estos pacientes se mantiene bajo debate. Objetivos: evaluar factibilidad, seguridad y resultados en una serie inicial de resecciones abdómino-perineales laparoscópicas. Lugar de aplicación: Servicio de Cirugía General de Hospital Privado afiliado a la Universidad Nacional de La Plata. Diseño: estudio clínico observacional retrospectivo. Población: 12 pacientes intervenidos quirúrgicamente por cáncer de recto en los que se realizó resección abdómino-perineal laparoscópica, diciembre de 1994 y julio de 2002. Métodos: se analizan la técnica quirúrgica, el tiempo operatorio, las complicaciones intra operatorias y postoperatorias, la estadía hospitalaria y el seguimiento oncológico de cada paciente. Resultados: el tiempo operatorio promedio fue de 165 minutos. No hubo conversiones. Como complicaciones intraoperatorias registramos un caso de lesión vesical y enterotomía. El promedio de hospitalización fue de 7.6 días. El seguimiento máximo fue de 4 años y el mínimo de 1 mes y durante el mismo se constató una recurrencia loco-regional sin implantes en sitio de trócares. La mortalidad operatoria fue del 8.3 por ciento. Conclusiones: la resección abdómino-perineal laparoscópica por cáncer de recto es factible. Las ventajas del abordaje mininvasivo representadas por la menor alteración del status inmunológico, disminución de la morbilidad como así también el mayor confort postoperatorio la hacen una alternativa válida frente a la cirugía convencional
Subject(s)
Humans , Male , Female , Middle Aged , Aged , Rectal Neoplasms/surgery , Laparoscopy , Retrospective Studies , Minimally Invasive Surgical Procedures/trendsABSTRACT
Antecedentes: el tratamiento laparoscópico del cáncer colorrectal plantea controversias desde el punto de vista de la cirugía oncológica. El rol de esta vía de abordaje en estos pacientes se mantiene bajo debate. Objetivos: evaluar factibilidad, seguridad y resultados en una serie inicial de resecciones abdómino-perineales laparoscópicas. Lugar de aplicación: Servicio de Cirugía General de Hospital Privado afiliado a la Universidad Nacional de La Plata. Diseño: estudio clínico observacional retrospectivo. Población: 12 pacientes intervenidos quirúrgicamente por cáncer de recto en los que se realizó resección abdómino-perineal laparoscópica, diciembre de 1994 y julio de 2002. Métodos: se analizan la técnica quirúrgica, el tiempo operatorio, las complicaciones intra operatorias y postoperatorias, la estadía hospitalaria y el seguimiento oncológico de cada paciente. Resultados: el tiempo operatorio promedio fue de 165 minutos. No hubo conversiones. Como complicaciones intraoperatorias registramos un caso de lesión vesical y enterotomía. El promedio de hospitalización fue de 7.6 días. El seguimiento máximo fue de 4 años y el mínimo de 1 mes y durante el mismo se constató una recurrencia loco-regional sin implantes en sitio de trócares. La mortalidad operatoria fue del 8.3 por ciento. Conclusiones: la resección abdómino-perineal laparoscópica por cáncer de recto es factible. Las ventajas del abordaje mininvasivo representadas por la menor alteración del status inmunológico, disminución de la morbilidad como así también el mayor confort postoperatorio la hacen una alternativa válida frente a la cirugía convencional
Subject(s)
Humans , Male , Female , Middle Aged , Laparoscopy , Rectal Neoplasms , Minimally Invasive Surgical Procedures/trends , Retrospective StudiesABSTRACT
OBJECTIVE: It has been suggested that the incidence of multiple sclerosis (MS) in Mexico and other countries of Latin America has increased steadily for the last two decades. We made a thorough search of antecedents on MS patients that could be potential risk factors. METHODS: A case-control study was conducted using a questionnaire that included demographic, nutritional, infectious and personal antecedents previously identified in other reports as possible risk factors for MS. RESULTS: The frequency of varicella, ephemeral breastfeeding and eczema in the medical history of MS patients were significant when compared with controls; all appeared to be mutually additive. However, they were unrelated with clinical characteristics or disease severity. CONCLUSION: During the last decades, breastfeeding has been abandoned in large segments of society and the incidence of varicella and childhood eczema keeps a north-south gradient similar to that described for MS. These factors may participate in the sharp increase of MS in countries like Mexico traditionally considered as an area of very low incidence.
Subject(s)
Breast Feeding/adverse effects , Chickenpox/complications , Eczema/complications , Ephemeral Fever/complications , Multiple Sclerosis/etiology , Animals , Case-Control Studies , Cattle , Female , Humans , Male , Mexico , Middle Aged , Risk Factors , Severity of Illness Index , Socioeconomic FactorsABSTRACT
CD40 binding produces multifaceted growth signals in normal and malignant B cells, whereas its physiological role is less well characterized in epithelial cancers. We examined the growth outcome of CD40 ligation in human breast cancer cells, using CD40+ (T47D and BT-20) and CD40-negative (MCF-7, ZR-75-1) cell lines as defined by flow cytometric analysis, immunohistochemistry, and reverse transcription-PCR. Treatment with the soluble recombinant CD40 ligand (CD40L) molecules gp39 or CD40L-trimer significantly reduced [3H]thymidine uptake in BT-20 and T47D cells by up to 40%, but did not affect the growth of CD40-negative MCF-7 or ZR-75-1 cells. Similarly, significant growth inhibition was observed after co-incubation with CD40L-transfected murine L cells (55.0 +/- 8.9%, P < 0.001) that express membrane CD40L constitutively, or with paraformaldehyde-fixed, CD3+ CD40L+ PBLs from three different HLA-mismatched donors (39.7 +/- 3.7%, P < 0.01). Untransfected L cells and non-CD40L-expressing lymphocytes did not produce significant growth inhibition. The in vivo antitumorigenic effects of CD40L were examined using a s.c. severe combined immunodeficient-hu xenograft model. Pretreatment with two different soluble recombinant CD40L constructs (CD40L and gp39) produced similar xenograft growth-inhibitory effects [67 +/- 24% (n = 4), and 65 +/- 14% (n = 8) inhibition, respectively], which were reversed by co-treatment with the CD40L-neutralizing antibody LL48. In vitro analysis indicated that CD40L-induced growth inhibition was accompanied by apoptotic events including cell shrinkage, rounding, and detachment from the adherent T47D culture monolayer. Thirty-one and 27% of gp39-treated T47D and BT-20 cells underwent apoptosis, respectively, as compared with 56 and 65% from the same cell lines after treatment with the Fas agonistic antibody CH-11. An up-regulation of the proapoptotic protein Bax in T47D and BT-20 cells was observed, which indicated that this Bcl-2 family member may contribute to this growth-inhibitory effect. To explore the clinical relevance of CD40L-CD40 interaction, retrospective immunohistochemical analysis was carried to characterize in situ CD40- and CD40L-expression in breast cancer patient biopsies. All of the infiltrating ductal (5 of 5 cases tested) and lobular (4 of 4 cases) breast carcinomas, carcinomas in situ (6 of 6 cases), and mucinous carcinoma tested (1 case) expressed CD40. Varying proportions of tumor cells also expressed CD40L in the majority of infiltrating ductal (3 of 5 cases) and lobular (3 of 4 cases) carcinomas, and carcinomas in situ (4 of 6 cases), as determined by immunohistochemistry and validated by RT-PCR detection of the CD40L message in only CD40L positive-staining cases. Tumor infiltrating mononuclear cells from infiltrating carcinomas and carcinomas in situ expressed CD40 (10 of 10 cases), but less commonly CD40L (1 case of infiltrating lobular carcinoma, 2 cases of carcinoma in situ). Our findings indicate that the CD40 signaling pathway is active in human breast carcinoma cells. However, tumor-infiltrating lymphocytes from primary tumor tissues may be limited in their capacity to directly modulate tumor growth through the CD40L-CD40 loop.
Subject(s)
Breast Neoplasms/drug therapy , Breast Neoplasms/metabolism , CD40 Ligand/biosynthesis , CD40 Ligand/pharmacology , Animals , Annexin A5/metabolism , Apoptosis , Blotting, Western , CD40 Antigens/metabolism , Carcinoma/metabolism , Cell Division/drug effects , Dimerization , Flow Cytometry , Humans , Immunohistochemistry , In Situ Nick-End Labeling , Leukocytes, Mononuclear/metabolism , Mice , Mice, SCID , Neoplasm Transplantation , Recombinant Proteins/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Ribonucleases/metabolism , Thymidine/metabolism , Time Factors , Transfection , Tumor Cells, Cultured , Up-RegulationABSTRACT
The purpose of this study is to determine immune recovery and function after treatment with docetaxel or paclitaxel. Peripheral blood mononuclear cells were harvested before chemotherapy and at weekly times afterwards for cycle 1. Leukocyte subsets ICD45hiCD14lo polymorphonuclear neutrophils, CD45hiCD14hi monocytes, CD45hiCD14- lymphocytes, CD3+CD4/CD8+ T cells, CD3-CD19+ B cells, CD3-CD16/CD56+ natural killer (NK) cells], and circulating cytokine levels [tumor necrosis factor-alpha, gamma-interferon (gamma-IFN), and interleukins (IL-2, IL-10, IL-12)] were followed. In addition, T-cell mitogenic function, NK function, and lymphokine activated killer (LAK) function was assessed. Ten patients were entered in the trial. T-cell frequency, B-cell frequency, and CD4/CD8 ratio did not change. IL-10 serum levels significantly decreased in paclitaxel-treated patients (4.4+/-1.3 pg/ml at week 4 versus 7.8+/-2.1 pg/ml at baseline; p < 0.05). IL-2, IL-12, and gamma-IFN levels were not detectable. NK cytotoxic activity decreased in docetaxel-treated patients. LAK cell activity was not altered. Four patients achieved a partial or complete response. They demonstrated higher than normal CD4:CD8 T-cell ratios and an improved phytohemagglutinin stimulation index (SI = 2.5). In conclusion, our findings suggest that immune function was affected more significantly after docetaxel treatment. Investigational approaches, which enhance cellular immunity, may be of greater relevance after treatment with docetaxel. Additional studies monitoring NK function after chemotherapy are recommended.
Subject(s)
Antineoplastic Agents, Phytogenic/pharmacology , Cytokines/blood , Cytotoxicity, Immunologic/drug effects , Immunity, Cellular/drug effects , Killer Cells, Natural , Paclitaxel/analogs & derivatives , Paclitaxel/pharmacology , Taxoids , Aged , Antineoplastic Agents, Phytogenic/therapeutic use , Docetaxel , Female , Humans , Immunophenotyping , Killer Cells, Lymphokine-Activated , Killer Cells, Natural/drug effects , Lymphocyte Activation , Lymphocyte Subsets , Male , Middle Aged , Neoplasms/drug therapy , Neoplasms/immunology , Paclitaxel/therapeutic useABSTRACT
The objective of this study is to provide information and a conceptual framework that will facilitate the work of persons in charge of systematizing institutions devoted to environmental health. The notion of "environment" is examined and a definition is proposed, while a look is also taken at the place held by environmental health within the context of environmental problems and their "green" and "blue" components. A number of definitions are put forth before presenting the official definition of environmental health issued by WHO in Sofia (1993). Subsequently a list is presented of the basic areas that have been assigned to the field of environmental health by different organizations or at various meetings, with PAHO, WHO, and Program 21 among them. From this a rather exhaustive list of areas and subareas is constructed, with the finding that all lists are, in reality, an asystematic grouping of three different components: determining factors (from the physical world), processes (types of interventions), and roles (series of administrative tasks) which can be conceived as a matrix and which allow for the description of individual activities by the environmental health services. Certain rules of operation are proposed which make it possible, through a form of algebra, to construct expressions for describing such activities and their aggregates with some precision. Thus, it becomes possible to employ a common symbolic language which can facilitate intercommunication, teaching, and research in the area of environmental health.
Subject(s)
Environmental Health , Environmental Pollution/prevention & control , Environmental Health/standards , Environmental Health/statistics & numerical data , Environmental Monitoring , Pan American Health Organization , Terminology as Topic , World Health OrganizationABSTRACT
We and others previously demonstrated that human multiple myeloma (MM) cells express CD40 and have an active CD40-growth regulatory pathway. This study characterizes the growth outcome of soluble (gp39) or membrane-bound recombinant human CD40-ligand (rCD40L) and its relationship with Fas-dependent apoptosis. Contrary to the moderate growth-stimulatory effect of the CD40-MAb G28.5, gp39 inhibited 3H-thymidine uptake of the plasma dyscrasia lines ARH-77, U266, and HS-Sultan in a dose-dependent fashion by up to 82%. By comparison, RPMI 8226 cells were resistant to CD40L-growth modulation, which may be attributable to a single base substitution (TCA-->TTA, serine-->leucine) at the 3rd cysteine-rich extramembrane region of CD40. Gp39 similarly reduced myeloma clonogenic colony (MCC) formation in patient primary bone marrow cultures by 50% (40-76%; n=6). Studies using transfectant L cells that constitutively expressed CD40L showed that membrane-bound CD40L inhibited the growth of ARH-77, U266, and HS-Sultan cells (66%, 63%, and 32%, respectively), whereas untransfected L cells did not. Growth inhibition by gp39 or CD40L+ L cells was neutralized by coincubation with the CD40L antibodies 5c8 or LL48. CD40L-treatment increased apoptotic activity of MM cells, as defined by oligonucleosomal DNA fragmentation and an increased binding to annexin V (16-28%). All three untreated CD40-responsive MM lines expressed the Fas/Apo-1/CD95 antigen (65-92% CD95+). However, only ARH-77 cells responded to the growth inhibitory effect of the CD95-agonistic antibody CH-11. CD95 expression was not affected significantly by gp39 treatment, and growth inhibition by CH-11 was additive to gp39 (from 42% to 64% decrease in 3H-thmidine uptake). Conversely, the CD95 antagonist antibody ZB4 reversed the Fas-dependent growth inhibitory process but did not significantly alter gp39-mediated growth outcome. Gp39 treatment lowered the expression of TNFR-associated factors TRAF4 and TRAF6 by 38% and 32%, respectively, whereas detectable levels of TRAF1,2,3, and 5 levels remained unchanged. Our observations indicate that the CD40L-binding inhibits human MM cell growth and increases its apoptotic activity. This growth inhibitory effect corresponds to lower levels of cytoplasmic TRAF signaling elements, and appears independent of the Fas-signaling pathway. CD40 receptor mutation may lead to unresponsiveness to CD40 growth modulation in multiple myeloma cells.
Subject(s)
Apoptosis/drug effects , Membrane Glycoproteins/pharmacology , Multiple Myeloma/pathology , fas Receptor/metabolism , CD40 Ligand , Humans , Immunotherapy , Membrane Glycoproteins/metabolism , Multiple Myeloma/immunology , Multiple Myeloma/metabolism , Multiple Myeloma/therapy , Recombinant Proteins/metabolism , Signal Transduction , Tumor Cells, CulturedABSTRACT
Between November 1993 and March 1994, a cluster 6 pediatric patients with acute febrile illnesses associated with rashes was identified in Jujuy Province, Argentina. Immunohistochemical staining of tissues confirmed spotted fever group rickettsial infection in a patient with fatal disease, and testing of serum of a patient convalescing from the illness by using an indirect immunofluorescence assay (IFA) demonstrated antibodies reactive with spotted fever group rickettsiae. A serosurvey was conducted among 16 households in proximity to the index case. Of 105 healthy subjects evaluated by IFA, 19 (18%) demonstrated antibodies reactive with rickettsiae or ehrlichiae: 4 had antibodies reactive with Rickettsia rickettsii, 15 with Ehrlichia chaffeensis, and 1 with R. typhi. Amblyomma cajennense, a known vector of R. rickettsii in South America, was collected from pets and horses in the area. These results are the first to document rickettsial spotted fever and ehrlichial infections in Argentina.
Subject(s)
Ehrlichia chaffeensis/isolation & purification , Ehrlichiosis/epidemiology , Rickettsia rickettsii/isolation & purification , Rocky Mountain Spotted Fever/epidemiology , Adolescent , Adult , Antibodies, Bacterial/blood , Argentina/epidemiology , Child , Child, Preschool , Ehrlichia chaffeensis/immunology , Fatal Outcome , Female , Fluorescent Antibody Technique , Humans , Immunoenzyme Techniques , Male , Rickettsia rickettsii/immunology , Rocky Mountain Spotted Fever/physiopathology , Seroepidemiologic StudiesABSTRACT
Diabetes (type I and type II) affects approximately 13 million people in the United States. Delayed and incomplete healing of wounds can be a major problem for diabetic patients. Macrophages are an important cell in the complex process of wound repair representing the major source of cytokines throughout the wound-healing process. Cytokines mediate many of the cellular responses critical to timely wound repair. It has been suggested that diabetes impairs wound healing through disruption of local cytokine production. Our previous in vivo studies in rats demonstrated that diabetes-induced and diet-induced hyperlipidemia cause changes in macrophage phenotype and function (Iacopino 1995; Doxey et al. 1998), suggesting that alterations in macrophage cytokine profiles represent the cellular/molecular mechanism responsible for delayed wound healing. The purpose of this study was to investigate how monocyte maturation/differentiation and cytokine production were altered by serum lipids in an in vitro system using human cells. Commercially prepared purified human monocytes were cultured and exposed to serum lipids. Phenotypic analysis of differentiated macrophages was then performed by flow cytometry and fluorescent microscopy using surface antigens specific for various macrophage subsets. Selected cytokines in conditioned medium were assayed using commercial human enzyme-linked immunosorbent assay (ELISA) kits. We demonstrate that serum lipids cause an increase in monocytic differentiation leading to an inflammatory macrophage phenotype rather than a reparative/proliferative phenotype. We also show that serum lipids cause a generalized decrease in macrophage cytokine production using interleukin-1 beta (IL-1 beta), tumor necrosis factor alpha (TNF-alpha), platelet-derived growth factor (PDGF), and transforming growth factor beta 1 (TGF-beta 1) as marker cytokines. Our present in vitro results using human cells confirm our previous in vivo studies in the rat and support the hypothesis that diabetes-induced hyperlipidemia alters the monocyte differentiation process resulting in changes of macrophage subsets and cytokine release at the wound site, ultimately impairing the wound-healing process.
Subject(s)
Cytokines/biosynthesis , Lipids/blood , Macrophages/cytology , Macrophages/physiology , Monocytes/physiology , Animals , Cell Differentiation , Cells, Cultured , Cytokines/analysis , Enzyme-Linked Immunosorbent Assay , Flow Cytometry , Humans , Interleukin-1/biosynthesis , Macrophages/immunology , Monocytes/cytology , Monocytes/immunology , Platelet-Derived Growth Factor/biosynthesis , Rats , Transforming Growth Factor beta/biosynthesis , Tumor Necrosis Factor-alpha/biosynthesisABSTRACT
Asthma remains the second most common cause for admissions to a paediatric hospital bed. The aim of this study was to describe the characteristics of children admitted to hospital with an acute asthma attack and to identify factors that may prevent future hospital admissions. Parents of all children aged 3 to 15 years admitted to hospital for acute asthma were interviewed and the child's case record reviewed. Children were recruited consecutively in two groups: 141 summer/autumn and 125 winter/spring 1996. According to the pattern of symptoms in the previous 12 months, 61% of the children had infrequent episodic asthma, 26% had frequent episodic asthma, and 13% persistent asthma. Only 8% of children aged 8 years or less had persistent asthma, in contrast to 22% of those aged > 8 years. There was evidence of both inadequate prescription of preventive treatment and poor compliance in the frequent episodic and persistent asthma groups. Of the whole group, 44% had previously been given an acute asthma management plan, but only 9% of them used it before the current hospital admission. There was a delay in seeking medical advice (> 24 hours after the onset of symptoms) in 27% of all admissions. This study has identified potential areas where intervention may reduce the number of future admissions.
Subject(s)
Asthma/prevention & control , Acute Disease , Adolescent , Anti-Inflammatory Agents/therapeutic use , Asthma/drug therapy , Child , Child, Preschool , Emergencies , Female , Hospitalization , Humans , Male , Patient Acceptance of Health Care , Patient Compliance , Patient Education as Topic , Prednisolone/therapeutic use , Prospective Studies , Time FactorsABSTRACT
A fast and simple experimental method of arterioplasty that produces enduring enlargement of the lumen of large arteries is described. We studied the long-term intraluminal patency of femoral arteries of four dogs subjected to a procedure in which a longitudinal 3-cm loophole was made in the artery and left open inside a girdling cylinder of glutaraldehyde-tanned calf pericardium. One year later, Doppler ultrasound and histological studies were performed in the operated and contralateral arteries. Lasting enlargement of the lumen was obtained along the 3-cm arteriotomy. The mean cross-sectional internal diameter in the middle of the surgical area was 2.2 +/- 0.1 mm, in contrast to 1.2 +/- 0.2 mm in the non-operated contralateral artery (P < 0.01). The ultrasound study showed an increase in blood flow and histological analysis demonstrated a threefold increase in the internal area of the arterial lumen, and new endothelium, which fully covered the operated segment. Our results showed an enduring increase in the lumen in segments of large arteries subjected to our new arterioplasty procedure.